Role of Craving in the Transition Across Level of Addiction Severity: A Longitudinal Study.
ConditionAddiction
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Bordeaux
About this trial
Substance/Alcohol Use disorders are defined as a loss of control over the use despite harmul consequences, as well as an intense and persistent urge to use, also called craving. Previous research has shown that craving is central among the diagnostic criteria for addiction, suggesting that it may be important in the onset and persistence of addiction.
Addiction develops progressively, and it appears crucial to identify predictive markers of the transition from one level of severity to another over time. One hypothesis is that more closely linked symptoms (meaning symptoms that influence each other more) could be associated with greater severity and/or with the evolution of addiction severity over time.
The aim of this project is to explore how the characteristics of the association between addiction symptoms (diagnostic criteria and symptoms as they occur in daily life), and the importance of craving relative to other symptoms, could serve as markers of different addiction severities and of the transition across these levels of severity.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Be over 18 years of age
Identify a primary substance as a main problematic substance use.
Be a regular user (at least twice a week in the last 30 days) of a primary substance (defined as their main problematic substance use).
Present a current diagnosis of SUD for this primary substance according to DSM-5 criteria.
Disqualifiers
Medical, psychiatric or addiction condition that warrants immediate inpatient treatment intervention.
Somatic, cognitive or other disorders preventing the use of the smartphone device (deafness, impaired vision, illiteracy….).
Not being familiar with the use of smartphone
Having a smartphone not compatible with the application and being unable to visit the laboratory to receive a loaner phone for the study.
Trial population
Patients who have initiated treatment for addiction in a Centre de Soin et d'Accompagnement et de Prévention en Addictologie in France; People with addiction recruited from the general population via recruitment campaigns (posters, partner institutions websites, newspaper, social media); Users of Kanopée, a smartphone application developed by SANPSY Lab, who reported problematic tobacco, alcohol or cannabis use.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Observational assessments (EMA and annual DSM-5 evaluations)
Other interventionParticipants are observed over two years. Annual DSM-5 diagnostic criteria for substance use disorders (SUD) are assessed, and participants complete 2-week EMA protocols measuring substance use, craving, and related factors four times per day. No intervention is administered.
Treatment groups
700 Participants
are divided into 5 treatment groupsGroup A: Alcohol1 intervention
Group B: Tobacco1 intervention
Group C: Cannabis1 intervention
Group D: Opiates1 intervention
Group E: Stimulants1 intervention
Trial outcomes
Primary outcomes
1
Craving centrality in the DSM-5 Substance Use Disorder diagnostic criteria network
Craving centrality will be quantified as the expected influence centrality of the DSM-5 craving criterion within a cross-sectional network including the 11 DSM-5 Substance Use Disorder diagnostic criteria. Expected influence values will be estimated for each assessment (baseline, 1-year and 2-year follow-up) and compared across addiction severity groups and severity transition groups.
Time frame
Baseline, 1-year follow-up, 2-year follow-up2
Global connectivity of the DSM-5 Substance Use Disorder diagnostic criteria network
Global network connectivity will be quantified as global strength (sum of absolute edge weights) of the DSM-5 diagnostic criteria network. Global strength estimates will be compared across addiction severity groups and severity transition groups.
Time frame
Baseline, 1-year follow-up, 2-year follow-up3
Predictability of nodes in the DSM-5 Substance Use Disorder diagnostic criteria network
Node predictability will be calculated as the proportion of variance explained (R²) for each DSM-5 diagnostic criterion by its neighboring nodes within the network. Mean node predictability will be reported and compared across addiction severity groups and severity transition groups.
Time frame
Baseline, 1-year follow-up, 2-year follow-up4
Differences in DSM-5 Substance Use Disorder diagnostic criteria network structure
Differences in overall network structure and global strength between addiction severity groups and severity transition groups will be evaluated using the Network Comparison Test (NCT). The reported outcome will be the statistical significance of differences in network structure.
Time frame
Baseline, 1-year follow-up, 2-year follow-upSponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Bordeaux
Lead sponsor
Hospices Civils de Lyon
Collaborator
Source ClinicalTrials.gov